Evaluation of the in-vitro activity of furopenem (SY5555 or SUN5555) against respiratory tract pathogens and β-lactamase producing bacteria

Abstract

Furopenem is a novel orally active penem. In this study, furopenem was highly active in vitro against Streptococcus pneumoniae (MIG₉₀ 0.03 mg/L), Haemophilus influenzae (MIC₉₀, 2 mg/L), and Moraxella catarrhalls (MIG₉₀, 0.5 mg/L). Its activity was not reduced by a variety of β-lactamase enzymes, however β-lactam resistance by other mechanisms was associated with higher MICs.